(Q46437713)

English

Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy

scientific article published in May 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

0 references

1 reference

based on heuristic

inferred from title

disease biology

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Vikas Gupta

1

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

Kathy Chun

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

Qi-Long Yi

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

Mark Minden

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

Andre Schuh

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

Richard Wells

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

Joseph Brandwein

7

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

language of work or name

0 references

publication date

1 May 2005

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

103

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

10

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

2082-2090

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

21 January 2018

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute myelogenous leukaemia in older patients at St Bartholomew's Hospital: outcome with mitoxantrone and cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Failure of remission induction in acute myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of acute myeloid leukemia in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21006

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21006

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/15830348

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46437713&oldid=2111705889"